Rockefeller Capital Management’s AbCellera Biologics ABCL Stock Holding History

Rockefeller Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$147K	Buy	10,085 +508	+5%	+$4.82K	﹤0.01%	2848
2026 Q2	$75.2K	Buy	9,577 +7,577	+379%	+$37K	﹤0.01%	3144
2026 Q1	$6.98K	Hold	2,000	–	–	﹤0.01%	4136
2025 Q4	$6.84K	Sell	2,000 -500	-20%	-$2.23K	﹤0.01%	3956
2025 Q3	$12.6K	Buy	+2,500	New	+$11K	﹤0.01%	3560
2023 Q1	–	Sell	-500	Closed	-$5K	–	1974
2022 Q4	$5K	Buy	+500	New	+$5.78K	﹤0.01%	3303
2022 Q3	–	Sell	-500	Closed	-$5K	–	3834
2022 Q2	$5K	Sell	500 -135	-21%	-$1.14K	﹤0.01%	3415
2022 Q1	$6K	Buy	635 +135	+27%	+$1.28K	﹤0.01%	3252
2021 Q4	$7K	Hold	500	–	–	﹤0.01%	3123
2021 Q3	$10K	Buy	+500	New	+$8.84K	﹤0.01%	2874

Other funds holding ABCL

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

DnB Asset Management Oslo, Norway $38B AUM 25.01% 1-Year Est. Return

Rockefeller Capital Management's ABCL Position: Q3 2026 in Review

Rockefeller Capital Management increased its AbCellera Biologics (ABCL) stake by 5.3% in Q3 2026, buying an estimated $4.82K and bringing the position to 10,085 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

Rockefeller Capital Management first reported a position in ABCL in Q3 2021 and has held it in 10 quarters since. 110 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

Rockefeller Capital Management held 10,085 shares of AbCellera Biologics worth $147K as of Q3 2026.
Rockefeller Capital Management bought 508 AbCellera Biologics shares in Q3 2026, an estimated $4.82K.
AbCellera Biologics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #2848 holding.
Rockefeller Capital Management first reported a position in AbCellera Biologics in Q3 2021 and has held it in 10 quarters since.
110 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.